Autopsy report · NCT04839575

Study of Latiglutenase in T1D/CD Patients

“Covid-19 interruptions and enrollment challenges”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 8 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Entero Therapeutics

Sponsor type

Industry

Conditions

Celiac Disease

Interventions

Latiglutenase; Placebo

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• Oxidative Stress and Circulating Nuclear DNA (cfDNA) in Acute Kidney Injury and Continuous Renal Replacement Therapies.
  “Enrollment slower than anticipated and interrupted by COVID-19 pandemic” (78% match in meaning)
• Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
  “Enrollment halted prematurely due to the Covid-19 pandemic” (76% match in meaning)
• A Comparison of Stryker's Tritanium Posterior Lumbar Cage and PEEK Implant
  “Due to COVID-19 disruption” (74% match in meaning)
• Effects of rTMS on Human Brain Activity
  “Never started enrollment due to COVID-19 closures” (74% match in meaning)
• Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
  “Enrollment was affected due to the COVID-19 pandemic” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.